Drug intelligence / Profile preview

zosurabalpin

Development stage: Phase 1
Lead developer: Roche
Modality: Cyclic Peptides → Modified Peptides → Peptides
Administration: Intravenous

Overview

Zosurabalpin is an experimental *tethered macrocyclic peptide* (MCP) antibiotic developed by Roche and scientists from Harvard University. It targets *Acinetobacter baumannii* by inhibiting the LptB2FGC complex, disrupting lipopolysaccharide (LPS) transport, which leads to the accumulation of toxic intermediates and bacterial death. It is particularly effective against carbapenem-resistant strains and has shown potent activity in both in vitro and in vivo models. Zosurabalpin is being developed for the treatment of infections caused by carbapenem-resistant *Acinetobacter baumannii* (CRAB).

Other names: RG6006RG-6006RG 6006Abx MCPRO7223280RO-7223280RO 7223280

Targets

LptC (Lipopolysaccharide export system protein LptC)

Beyond the preview

Go deeper on zosurabalpin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zosurabalpin.

Explore the full profile